News | February 16, 2022
Clean Science and Technology to invest Rs. 300 - 500 Cr on expansion
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
The entire integration and transition of the brands is expected to be completed by March 2022
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Key takeaways of Q3FY22 quarter & conference call highlights
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Key takeaways of recent quarter & conference call highlights
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Subscribe To Our Newsletter & Stay Updated
